Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...

Bibliografski detalji
Glavni autori:	Sun Joo Cha, Kiyoung Kim
Format:	Članak
Jezik:	English
Izdano:	MDPI AG 2022-01-01
Serija:	Antioxidants
Teme:	edaravone oxidative stress antioxidant mitochondria neurodegenerative disease amyotrophic lateral sclerosis
Online pristup:	https://www.mdpi.com/2076-3921/11/2/195

Slični predmeti

A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
od: Erdi Şahin
Izdano: (2018-03-01)

Edaravone: A new hope for patients with amyotrophic lateral sclerosis
od: Shivangi Garg, i dr.
Izdano: (2019-01-01)

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
od: Hideki Houzen, i dr.
Izdano: (2021-07-01)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
od: Jin-Mo Park, i dr.
Izdano: (2022-07-01)

Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
od: Chang Liu, i dr.
Izdano: (2024-10-01)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
od: Hee Jo Han, i dr.
Izdano: (2022-12-01)

New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments
od: Maria A. Lapshina, i dr.
Izdano: (2023-11-01)

Bulbar Onset Amyotrophic Lateral Sclerosis: A Case Report
od: Kabindra Rai, i dr.
Izdano: (2023-02-01)

The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
od: Jiantao Zhao, i dr.
Izdano: (2022-06-01)

Recent Advances on the Role of GSK3β in the Pathogenesis of Amyotrophic Lateral Sclerosis
od: Hyun-Jun Choi, i dr.
Izdano: (2020-09-01)

Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
od: Benjamin Rix Brooks, i dr.
Izdano: (2022-10-01)

Iranian clinical practice guideline for amyotrophic lateral sclerosis
od: Reza Boostani, i dr.
Izdano: (2023-06-01)

Amyotrophic lateral sclerosis – aetiology, diagnostics and multidirectional, team, long-term care
od: Kamila Tuzim, i dr.
Izdano: (2018-08-01)

Amyotrophic lateral sclerosis – aetiology, diagnostics and multidirectional, team, long-term care
od: Kamila Tuzim, i dr.
Izdano: (2018-08-01)

The Protective Effect of Edaravone on TDP-43 Plus Oxidative Stress-Induced Neurotoxicity in Neuronal Cells: Analysis of Its Neuroprotective Mechanisms Using RNA Sequencing
od: Aki Soejima-Kusunoki, i dr.
Izdano: (2022-07-01)

Amyotrophic lateral sclerosis with frontotemporal dementia
od: Corina Roman-Filip, i dr.
Izdano: (2010-09-01)

Synthesis and Characterization of Edaravone Analogues as Remyelinating Agents and Putative Mechanistic Probes
od: Eleonora Colombo, i dr.
Izdano: (2023-10-01)

Advancements and challenges in amyotrophic lateral sclerosis
od: David Bradford, i dr.
Izdano: (2024-05-01)

Intestinal Microbiota and Sclerosis Lateral Amyotrophic
od: Mariana Dantas de Carvalho Vilar, i dr.
Izdano: (2022-03-01)

The implications of DNA methylation for amyotrophic lateral sclerosis
od: ADRIANA HELENA DE OLIVEIRA REIS, i dr.
Izdano: (2023-10-01)

The role of statins in amyotrophic lateral sclerosis: protective or not?
od: Hayder M. Al-kuraishy, i dr.
Izdano: (2024-06-01)

Evaluation of Sensory Nerve Conduction Abnormalities in Patients with Amyotrophic Lateral Sclerosis
od: Waseem H. Alkhaffaf
Izdano: (2021-06-01)

New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis
od: Frances Theunissen, i dr.
Izdano: (2021-11-01)

Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704
od: Dong Wook Kang, i dr.
Izdano: (2021-09-01)

Prevalence of amyotrophic lateral sclerosis in Latium region, Italy
od: Maria Puopolo, i dr.
Izdano: (2021-12-01)

Mechanistic Insights of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis: An Update on a Lasting Relationship
od: Niccolò Candelise, i dr.
Izdano: (2022-03-01)

Progress in the study of mitochondrial dysfunction in pathogenesis of amyotrophic lateral sclerosis
od: LIU Liyang, LIU Qing, LIU Yaping, ZHANG Xue
Izdano: (2023-02-01)

Amyotrophic lateral sclerosis: pathogenetic mechanisms and new approaches to pharmacotherapy (literature review)
od: T. M. Alekseeva, i dr.
Izdano: (2019-01-01)

Commentary: Urinary Neopterin, a New Marker of the Neuroinflammatory Status in Amyotrophic Lateral Sclerosis
od: Gisele Espíndola, i dr.
Izdano: (2021-03-01)

Assessment of therapeutic response of edaravone and riluzole combination therapy in amyotrophic lateral sclerosis patients
od: Swapnil Samadhiya, i dr.
Izdano: (2022-01-01)

Oligodendrocytes in amyotrophic lateral sclerosis and frontotemporal dementia: the new players on stage
od: Marguerite Jamet, i dr.
Izdano: (2024-03-01)

Biomarkers of Amyotrophic Lateral Sclerosis: Current Status and Interest of Oxysterols and Phytosterols
od: Anne Vejux, i dr.
Izdano: (2018-01-01)

The Cell Autonomous and Non-Cell Autonomous Aspects of Neuronal Vulnerability and Resilience in Amyotrophic Lateral Sclerosis
od: Christoph Schweingruber, i dr.
Izdano: (2022-08-01)

Evaluation of Peripheral Immune Activation in Amyotrophic Lateral Sclerosis
od: Mengli Wang, i dr.
Izdano: (2021-06-01)

Depression in amyotrophic lateral sclerosis
od: Joanna Iłżecka
Izdano: (2021-10-01)

Amyotrophic lateral sclerosis : advances and perspectives of neuronanomedicine /
od: Machtoub, Lina, author, i dr.
Izdano: (2016)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
od: HaEun Cho, i dr.
Izdano: (2020-12-01)

Staging model for amyotrophic lateral sclerosis in Singapore
od: Yuan Teck Tay, i dr.
Izdano: (2022-07-01)

Analysis of SOD1 and C9orf72 mutations in patients with amyotrophic lateral sclerosis in Antioquia, Colombia
od: Jimena Jaramillo, i dr.
Izdano: (2022-12-01)

Pain in Amyotrophic Lateral Sclerosis Is Underrated
od: Soyoung Kwak, i dr.
Izdano: (2024-12-01)